<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H5073794E0AE943F6912A8DDAF8E00950" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5782 IH: Opioid Crisis Accountability Act of 2018</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-05-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5782</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180511">May 11, 2018</action-date><action-desc><sponsor name-id="G000571">Ms. Gabbard</sponsor> (for herself and <cosponsor name-id="K000389">Mr. Khanna</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committees on <committee-name committee-id="HED00">Education and the Workforce</committee-name>, <committee-name committee-id="HWM00">Ways and Means</committee-name>, and <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To hold pharmaceutical companies accountable for illegal marketing and distribution of opioid
			 products and for their role in creating and exacerbating the opioid
			 epidemic in the United States.</official-title></form>
	<legis-body id="HE7679C06DC444216B40CA1484CAB0787" style="OLC">
 <section id="HF74EBBF754AF49FA98E2E9E688A6DD89" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Opioid Crisis Accountability Act of 2018</short-title></quote>.</text> </section><section id="HBB7F5A77887B4403BB4949C1D3F6348A"><enum>2.</enum><header>Prohibition of illegal marketing and distribution practices with respect to opioids</header> <subsection id="H335B707501FB46F6BB2B14A86E6D38F3"><enum>(a)</enum><header>In general</header><text>Section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H76F91F69C6084423B8B80051D41DF092" style="OLC">
					<subsection id="HA5863E56C18D499684FF4BFF12F564BE"><enum>(h)</enum>
 <paragraph commented="no" display-inline="yes-display-inline" id="HC99FC8C9ED8A45538BB7CA36902AEA37"><enum>(1)</enum><text>In this subsection, the term <term>illegal marketing or distribution practice with respect to an opioid</term> means—</text> <subparagraph id="H755E64731FF3411F842DCAB78A7F8272" indent="up1"><enum>(A)</enum><text>including in any advertisement, promotion, direct-to-consumer marketing materials, or other marketing material a representation that an opioid has no addiction-forming or addiction-sustaining liability or has less of an addiction-forming or addiction-sustaining liability than 1 or more other opioids, knowing the representation to be false, as determined by the Secretary, in consultation with the Commissioner, based on research, testimonials, and other evidence;</text>
 </subparagraph><subparagraph id="H677E1474EDCD476DB9B8B85317C83151" indent="up1"><enum>(B)</enum><text>supplying States or communities with a quantity of opioids that is not medically reasonable, as determined by the Secretary, in consultation with the Attorney General using, if applicable, data from the Automated Reports and Consolidated Ordering System of the Department of Justice; or</text>
 </subparagraph><subparagraph id="H38BC53E0518E4AF7BEF143CE947F09D1" indent="up1"><enum>(C)</enum><text>failing to report to the Secretary any order or pattern of orders for the distribution of opioids that would cause a reasonable person to believe the opioids were not being dispensed in a medically reasonable manner.</text>
 </subparagraph></paragraph><paragraph id="H916E713EF09D42618F89C0FF7D73EC64" indent="up1"><enum>(2)</enum><text>It shall be unlawful for any person who manufactures or distributes an opioid to engage in an illegal marketing or distribution practice with respect to an opioid.</text>
						</paragraph><paragraph id="H0BB3ECA420DE4770BD8AD4C9CD9A0834" indent="up1"><enum>(3)</enum>
 <subparagraph commented="no" display-inline="yes-display-inline" id="H090D842EF9504E2EAC027EEEA647B933"><enum>(A)</enum><text>Any person who violates paragraph (2)—</text> <clause id="H357C6A15E363443AAED1CEF0BF808336" indent="up1"><enum>(i)</enum><text>if a natural person employed by an opioid manufacturer or distributor, shall be—</text>
 <subclause id="H3E0C18071A034FFEB59C18C0A28A2007"><enum>(I)</enum><text>subject to a civil penalty in an amount equal to the sum of—</text> <item id="HBAFC926835B84E68A2529306713BC608"><enum>(aa)</enum><text>such person’s full amount of salary for each year during which such person engaged in illegal marketing or distribution practices with respect to an opioid product; and</text>
 </item><item id="H9D9E659EBD4D4FEE8D2F032DB0EA2159"><enum>(bb)</enum><text>the amount by which the stock or other certificates of ownership interest of the person that is owned by the individual has increased in value during the period during which such person engaged in illegal marketing or distribution practices of an opioid product, without regard to whether the individual has sold any of the stock or certificates from such opioid manufacturer or distributor; and</text>
 </item></subclause><subclause id="H6DD42CB88B494996A4200494F5A62F93"><enum>(II)</enum><text>with respect to a violation that occurs on or after the date of enactment of the <short-title>Opioid Crisis Accountability Act of 2018</short-title>, subject to the period of imprisonment specified under section 401 of the Controlled Substances Act that would be applicable for a violation of subsection (a) of such section that involved the quantity of opioids that were involved in the illegal marketing or distribution practices with respect to an opioid;</text>
 </subclause></clause><clause id="HF56C8ECDDD664EF8B6845E3673A96299" indent="up1"><enum>(ii)</enum><text>if not a natural person, shall be subject to a civil penalty in the amount equal to the sum of—</text> <subclause id="HC1E692AF2ECB41FD94A3BFFE6163E856"><enum>(I)</enum><text>$7,800,000,000; plus</text>
 </subclause><subclause id="H481FE93462FC4B97A7310507A57701D6"><enum>(II)</enum><text>25 percent of the total profit such person made on lawful sales of opioids in the United States during the period in which the person engaged in illegal marketing or distribution practices.</text>
 </subclause></clause></subparagraph><subparagraph id="H942B279335CD47D397CF71BC4078030A"><enum>(B)</enum><text>If a person that is not a natural person violates paragraph (2), the court, without regard to the participation of such individuals in, or knowledge of such individuals of, the violation, shall—</text>
 <clause id="H7A2514EE3B2A4D05A25995EDF7F66E6B"><enum>(i)</enum><text>impose on the chief executive officer (or equivalent) of the person a civil penalty in an amount equal to the sum of—</text>
 <subclause id="HCC36ADA1F62B41B78DE06904565679DF"><enum>(I)</enum><text>the salary of the individual during the period in which the person engaged in illegal marketing or distribution practices and such individual served as chief executive officer; and</text>
 </subclause><subclause id="H9866F6587F604D18BA863E9A19CC5E24"><enum>(II)</enum><text>the amount by which the stock or other certificates of ownership interest of the person that is owned by the individual has increased in value during the period that the person engaged in illegal marketing or distribution practices and such individual served as chief executive officer, without regard to whether the individual has sold any of the stock or certificates;</text>
 </subclause></clause><clause id="H9B6C77E66B414AC28A80F7C3CCECD703"><enum>(ii)</enum><text>impose on any executive other than the chief executive officer (or equivalent) who led the finance, research, marketing, or sales department of the person a civil penalty in the amount equal to the sum of—</text>
 <subclause id="H8DDBF438DD6445E1B78FC8982D9F2632"><enum>(I)</enum><text>25 percent of the salary of the individual during the period that the person engaged in illegal marketing or distribution practices and such individual served as such an executive; and</text>
 </subclause><subclause id="HE0895E8EE2E84189B450167C21BAEDBD"><enum>(II)</enum><text>25 percent of the amount by which the stock or other certificates of ownership interest of the person that is owned by the individual has increased in value during the period that the person engaged in illegal marketing or distribution practices and such individual served as such an executive, without regard to whether the individual has sold any of the stock or certificates; and</text>
 </subclause></clause><clause id="H592FCFB205BF4570A622FC58944684F3"><enum>(iii)</enum><text>impose on any executive, including the chief executive officer (or equivalent) who led the finance, research, marketing, or sales department of the person during the calendar year in which a court enters a judgment that the person violated paragraph (2) and who is not subject to a civil penalty under clause (i) or (ii), a civil penalty in the amount equal to the sum of—</text>
 <subclause id="H0B5A89CFC09C43809D5862964FE01D27"><enum>(I)</enum><text>25 percent of the salary of the individual during the calendar year in which a court enters such judgment; and</text>
 </subclause><subclause id="H1CBB9DB739F2421CBE2577DFB3FB0CB6"><enum>(II)</enum><text>25 percent of the amount by which the stock or other certificates of ownership interest of the person that is owned by the individual has increased in value during the calendar year in which a court enters such judgment.</text>
 </subclause></clause></subparagraph><subparagraph id="H50C68E95EFDF41588A70DC97D6D28D2C"><enum>(C)</enum><text>Any person described in clause (i) or (ii) of subparagraph (A) shall be required to issue a public statement apologizing for their role in creating, sustaining, and exacerbating the opioid epidemic in the United States.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection><subsection id="H5DB3BB41EC954AB291A9F8E256A10F0B"><enum>(b)</enum><header>Investigation; retroactive effect</header>
 <paragraph id="H9B5D3938A9574472AEA871E1DBCB74BD"><enum>(1)</enum><header>Investigation</header><text>Immediately after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs and in consultation with the Attorney General, acting through the Administrator of the Drug Enforcement Administration, shall begin investigating all opioid manufacturers and all executives employed by such manufacturers to determine whether any such manufacturers or executives, at any time before or after such date of enactment, violated subsection (h)(2) of section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>) (as added by subsection (a)).</text>
 </paragraph><paragraph id="H053243FF4B014308A854EC41D55AF080"><enum>(2)</enum><header>Retroactive effect</header><text>Subsection (h)(2) of section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>) (as added by subsection (a)) shall take effect on January 1, 1985, and shall have retroactive effect.</text>
				</paragraph></subsection><subsection id="HE3AE10D533E04524B1A92E9B22F705A6"><enum>(c)</enum><header>Reimbursement of economic impact</header>
 <paragraph id="H4B78BD9319044163A6C91C912633AC5A"><enum>(1)</enum><header>Establishment of fund</header><text>There is established in the Treasury of the United States a fund, to be known as the <quote>Opioids Reimbursement Fund</quote> (referred to in this subsection as the <quote>Fund</quote>), to be administered by the Secretary of Health and Human Services (referred to in this subsection as the <quote>Secretary</quote>), in consultation with the Commissioner of Food and Drugs.</text>
 </paragraph><paragraph id="HF6565AC6E9CF42A1B8D6F4C925A4E260"><enum>(2)</enum><header>Transfers to the Fund</header><text>In a manner consistent with section 3302(b) of title 31, United States Code, there shall be transferred to the Fund from the General Fund of the Treasury an amount equal to the amount of the civil penalties collected under subsection (h)(3) of section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>) (as added by subsection (a)), which shall remain available until expended.</text>
				</paragraph><paragraph id="H2F1B63D150D043749FCD5E5E5989024E"><enum>(3)</enum><header>Use of funds</header>
 <subparagraph id="H22A8322E45AA4B3D97461333B4DC27B0"><enum>(A)</enum><header>In general</header><text>The Secretary, in consultation with the Commissioner of Food and Drugs, may, without further appropriation, use amounts in the Fund to combat the abuse of opioids in the United States, which may include transferring amounts from the Fund to other agencies to carry out programs, projects, and activities of the agencies to combat the abuse of opioids in the United States.</text>
 </subparagraph><subparagraph id="H9AED738972A7479092BA4F27EA64012F"><enum>(B)</enum><header>Priority</header><text>In using amounts in the Fund, the Secretary shall give priority to providing funds for—</text> <clause id="HBE5A08AC3C3D428BA86B9B49D6EB7B7B"><enum>(i)</enum><text>programs, projects, and activities of the Substance Abuse and Mental Health Services Administration, the Department of Labor, and the Department of Justice;</text>
 </clause><clause id="H02DCDC200CD64B7088598BFCCC894FB0"><enum>(ii)</enum><text>programs, projects, and activities that provide services to individuals directly affected by the abuse of opioids (including family members of such individuals);</text>
 </clause><clause id="H9BBA9EF84E224A0F9320568D5D45196E"><enum>(iii)</enum><text>programs, projects, and activities of the Department of Education related to national activities for school safety, including such activities authorized under section 4631 of the Elementary and Secondary Education Act of 1965 (<external-xref legal-doc="usc" parsable-cite="usc/20/7281">20 U.S.C. 7281</external-xref>) to help State and local educational agencies implement evidence-based opioid-abuse prevention strategies for schools in communities impacted by the opioid crisis, and particularly for any applicant who describes how such applicant would use the funds to prevent opioid abuse by students and address the mental health needs of students affected by opioid abuse with their families or communities; and</text>
 </clause><clause id="H330A1332CA244D4B909089DB035CFCC9"><enum>(iv)</enum><text>Head Start programs, including Early Head Start programs, under the Head Start Act (<external-xref legal-doc="usc" parsable-cite="usc/42/9831">42 U.S.C. 9831</external-xref> et seq.), to provide additional qualified child care providers trained in trauma-informed care in States with the largest number of children and families affected by the opioid crisis in their communities.</text>
 </clause></subparagraph><subparagraph id="HE6D075F9E9D54DE6BE428D6D83C06C2D"><enum>(C)</enum><header>Availability</header><text>Amounts transferred to an agency under subparagraph (A) shall remain available until expended.</text> </subparagraph></paragraph></subsection></section><section id="HEE76CA894D5F4FBF8B4BB4AC219A2809"><enum>3.</enum><header>Reduced exclusivity</header> <subsection id="H6147316A11EF4604975D5B031696BC02"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">If a drug manufacturer violates subsection (h)(2) of section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>) (as added by section 2) with respect to a covered opioid, effective on the date on which such manufacturer is found to have so violated such section—</text>
 <paragraph id="HAD29FB405E2A4B50818A2FB9B75F1AFE"><enum>(1)</enum><text display-inline="yes-display-inline">any remaining period of market exclusivity with respect to such covered opioid shall be revoked;</text> </paragraph><paragraph id="HFBDA7237BC6B4A8F9FCB0B2C07CD4277"><enum>(2)</enum><text display-inline="yes-display-inline">the period of market exclusivity with respect to any other opioid for which such manufacturer is the holder of an approved application under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or a license under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) shall be reduced to one half of the remaining period of market exclusivity; and</text>
 </paragraph><paragraph id="HD8EACE998DE84AF6ACB31D8659F29D3B"><enum>(3)</enum><text display-inline="yes-display-inline">no new or additional exclusivity shall be awarded to any opioid for which an application is submitted by such manufacturer for approval under section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>) or under section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>) or marketed as a result of product hopping.</text>
 </paragraph></subsection><subsection id="H237069A9405D4BE88F1DDBB5D07F5D5C"><enum>(b)</enum><header>Definitions</header><text>For purposes of this section:</text> <paragraph id="H737849181E0743E99B6827461D5C3047"><enum>(1)</enum><header>Covered opioid</header><text>A <term>covered opioid</term> is a prescription opioid drug, the sales of which in the United States, beginning on the date on which the drug was first eligible to be marketed in the United States and ending on the date on which the manufacturer was found to be in violation of subsection (h)(2) of section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>), has generated at least $1.</text>
 </paragraph><paragraph id="H5532E941C55742BF8D09C16A05530A7D"><enum>(2)</enum><header>Period of market exclusivity</header><text>The term <term>period of market exclusivity</term> with respect to a drug means the total period of market exclusivity granted under clause (ii), (iii), or (iv) of section 505(c)(3)(E) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(c)(3)(E)</external-xref>), section 505(j)(5)(B)(iv) of such Act, clause (ii), (iii), or (iv) of section 505(j)(5)(F) of such Act, section 527 of such Act, or section 351(k)(7) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)(7)</external-xref>), and any extension of such a period granted under section 505A or 505E of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a</external-xref>, 355f).</text>
 </paragraph><paragraph id="H9E351D680AC9487DB7C785B4607746AD"><enum>(3)</enum><header>Product hopping</header><text>The term <term>product hopping</term> means a reformulation of an approved drug or biological product that allows a manufacturer to submit a new drug application under section 505(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)</external-xref>) or new application for a license under section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>) and that—</text>
 <subparagraph id="H25B83EAA25C34E5D8A1BE97989C9806A"><enum>(A)</enum><text>is intended for the treatment of the same medical condition as the drug or biological product that was originally so approved; and</text>
 </subparagraph><subparagraph id="H2E78890BA6AB4F508B48CE8D03AA0947"><enum>(B)</enum><text>is undertaken in conjunction with the sponsor's actions to reduce or eliminate demand for the original formulation of the drug or biological product.</text>
 </subparagraph></paragraph></subsection></section><section id="HE7DAD3AEADAD46DB84312A9C8B305B33"><enum>4.</enum><header>Penalty with respect to opioids developed using Federal funding</header><text display-inline="no-display-inline">If a drug manufacturer or distributor violates subsection (h)(2) of section 303 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>) (as added by section 2) with respect to an opioid that was developed with the support of Federal funding, in addition to the applicable penalties under such subsection (h), such manufacturer or distributor shall be subject to a civil penalty in an amount equal to the sum of—</text>
 <paragraph id="H8686E4D215E24B6FB83BF3BB8E170831"><enum>(1)</enum><text display-inline="yes-display-inline">such Federal funding, regardless of whether the Federal funding was received by the manufacturer or distributor or another entity; plus</text>
 </paragraph><paragraph id="HF7739401260E45EBBB58BFA91C28A8AD"><enum>(2)</enum><text>25 percent of the total profit such manufacturer or distributor received in connection with manufacturing or distributing such opioid.</text>
			</paragraph></section><section id="H7AF789B2DFBE4756B9D30C328F66B7D2"><enum>5.</enum><header>Treatment of certain tax credits for violators of illegal marketing and distribution practices with
			 respect to opioids</header>
 <subsection id="HFF7CBF57FCC64CEE9C61E0692BB8DBA3"><enum>(a)</enum><header>In general</header><text><external-xref legal-doc="usc" parsable-cite="usc/26/41">Section 41</external-xref> of the Internal Revenue Code of 1986 is amended by adding at the end the following new subsection:</text>
				<quoted-block display-inline="no-display-inline" id="HB0153334EE724ED18B3D40DD6F3CA365" style="OLC">
					<subsection id="HFCABC5158B5645BD8EF173051B5A2610"><enum>(i)</enum><header>Treatment of certain taxpayers violating illegal marketing and distribution practices with respect
			 to opioids</header>
 <paragraph id="H24F0E75712D942D091CC0E3DBAB27ACD"><enum>(1)</enum><header>In general</header><text>In the case of any taxpayer who has engaged in an illegal marketing or distribution practice with respect to an opioid (within the meaning of section 303(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/333">21 U.S.C. 333</external-xref>))—</text>
 <subparagraph id="H3FB1CC4433CC414281597F0AEFA97159"><enum>(A)</enum><text>no credit shall be allowed under subsection (a), section 45C(a), or section 3111(f) for any taxable year in the applicable period, and</text>
 </subparagraph><subparagraph id="HEF0BF204DC3D4DB6AFC7F43773954812"><enum>(B)</enum><text>the taxpayer's tax under this chapter for the taxable year described in paragraph (2)(A) shall be increased by an amount equal to the amount of credits allowed to such taxpayer by reason of subsection (a), section 45C(a), and section 3111(f) for the period described in paragraph (2)(B).</text>
 </subparagraph></paragraph><paragraph id="H20A3A00FCE3D40A2876B1F29EFA24138"><enum>(2)</enum><header>Applicable period</header><text>For purposes of this subsection, the term <term>applicable period</term> means the period of taxable years which—</text> <subparagraph id="H202EB3D84BA24478AE9CD4BC19C3F1D7"><enum>(A)</enum><text>begins with the taxable year in which a civil penalty has been imposed for an illegal marketing or distribution practice with respect to an opioid under section 303(h)(3) of the Federal Food, Drug, and Cosmetic Act, and</text>
 </subparagraph><subparagraph id="H9B062F6A918F45A98597B59FAE0520E7"><enum>(B)</enum><text>has a duration equal to the number of taxable years in the period that begins with the first day on which the illegal marketing or distribution practice with respect to the opioid occurred and ends on the earlier of date on which—</text>
 <clause id="H8A07FC62F441478BA09035B7B19A2292"><enum>(i)</enum><text>the illegal marketing or distribution practice with respect to the opioid permanently ceased, or</text> </clause><clause id="HB5CCC93135C44292BD119CB35AB01121"><enum>(ii)</enum><text>the date on which the civil penalty described in subparagraph (A) is imposed.</text>
								</clause></subparagraph><continuation-text continuation-text-level="paragraph">For purposes of subparagraph (B), any portion of a taxable year that is less than a whole taxable
			 year shall be treated as a whole taxable year.</continuation-text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H907CF2A612CB40BB94DFAB5CDD4F4C1F"><enum>(b)</enum><header>Effective date</header><text>The amendments made by this section shall apply to taxable years ending after the date of the enactment of this Act.</text>
			</subsection></section></legis-body></bill>


